Trial Profile
A Phase Ib/II Trial of Taselisib (GDC-0032), a PI3K Inhibitor, in Combination With Enzalutamide in Patients With Androgen Receptor Positive Triple Negative Metastatic Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 23 Aug 2022
Price :
$35
*
At a glance
- Drugs Taselisib (Primary) ; Enzalutamide
- Indications Advanced breast cancer; Carcinoma; Male breast cancer; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- 03 Feb 2022 Planned End Date changed from 1 Dec 2021 to 1 Jul 2022.
- 05 Feb 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
- 27 Apr 2020 Planned End Date changed from 1 Dec 2021 to 1 Dec 2020.